SCHEMBL25035654

SCHEMBL25035654

Cc1nc(NS(=O)(=O)c2ccccc2C#N)ccc1-c1cc2cnc(N)nc2n(C(C)C)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.36
MTOR P42345 2/20 0.36
SLC40A1 Q9NP59 1/20 0.36
BRD1 O95696 1/20 0.35
BRPF1 P55201 1/20 0.35
TAS2R8 Q9NYW2 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
SGK1 O00141 1/20 0.34
PRF1 P14222 1/20 0.34
KMT2A Q03164 1/20 0.34
SLC22A12 Q96S37 2/20 0.33
EGFR P00533 1/20 0.33
FGFR1 P11362 1/20 0.33
SRC P12931 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
FGFR3 P22607 1/20 0.33
KDM1A O60341 1/20 0.33
BTK Q06187 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035541 0.88 EGFR (0.42) PIK3CAMTORALOX5APFEN1EGFR
SCHEMBL25035531 0.88 FEN1 (0.40) PIK3CAMTORALOX5APFEN1BTK
SCHEMBL25035528 0.88 PIK3CA (0.44) PIK3CAMTORSLC40A1BRD1BRPF1
SCHEMBL25034212 0.86 RXFP1 (0.41) PIK3CAMTORSLC40A1BRD1BRPF1
SCHEMBL25034241 0.86 ERN1 (0.36) PIK3CAMTORSLC40A1BRD1BRPF1
SCHEMBL25035635 0.85 BTK (0.38) PIK3CAMTORALOX5APFEN1EGFR
SCHEMBL22190781 0.82 ERN1 (0.51) FGFR1
SCHEMBL29358031 0.82 ERN1 (0.51) FGFR1
SCHEMBL22190779 0.82 ERN1 (0.51) FGFR1
SCHEMBL25035471 0.81 BTK (0.40) PIK3CAMTORBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD PIK3CA 211/4885MTOR 487/4885SLC40A1 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.